Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01663766 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Milatuzumab for Graft Versus Host Disease
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01663766 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 12 participants.
The verdict
NCT01663766, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
Interventions
- DRUG milatuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01663766
The ClinicalTrials.gov registry entry for NCT01663766 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which milatuzumab is the first listed.
NCT01663766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01663766 about?
NCT01663766 is a clinical study titled "Phase I Study of Milatuzumab for Graft Versus Host Disease". This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
What is the current status of trial NCT01663766?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-12. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01663766?
The interventions under investigation include: milatuzumab (DRUG).
Who is sponsoring clinical trial NCT01663766?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.